Yonghe Medical Group Co., Ltd. (YONGHE MEDICAL) announced that every resolution tabled at its Annual General Meeting held on 19 May 2026 was approved by poll.

Key outcomes

1. Financial Statements and Dividend • The audited consolidated results for the year ended 31 December 2025 were adopted with 100.00% support (401.30 million votes). • Shareholders endorsed a final dividend of RMB0.076 (HK$0.086) per share, excluding 248,000 treasury shares, also with 100.00% approval.

2. Board Composition • Executive Director Zhang Yu and Independent Non-executive Directors Liang Jihong, Chan Peng Kuan and Li Xiaopei were re-elected with support ranging from 96.93% to 100.00%. • The Board’s remuneration arrangement was unanimously authorised.

3. Auditor Re-appointment • PricewaterhouseCoopers was re-appointed as external auditor for the next financial year with 99.61% approval (399.73 million votes).

4. General Mandates • A 10% share repurchase mandate and a 20% issuance mandate (including disposal of treasury shares) were granted, each receiving at least 99.59% support. • An extension mandate allowing the Board to increase the issuance limit by the number of shares repurchased secured 96.58% approval.

5. Constitutional Amendment • The special resolution to amend the Memorandum and Articles of Association passed with 96.98% of votes cast (389.18 million in favour).

Voting base and attendance

• Shares eligible to vote: 525.22 million (excluding 248,000 treasury shares). • All seven Directors attended the meeting, and Tricor Investor Services Limited acted as vote scrutineer.

With all ordinary and special resolutions carried, YONGHE MEDICAL has secured shareholder backing for its 2025 financial distribution, refreshed director mandates and updated corporate governance framework.